Canaccord Genuity analyst Michelle Gilson maintained a Buy rating on Retrophin (NASDAQ:RTRX) on Tuesday, setting a price target of $28, which is approximately 30.17% above the present share price of $21.51.
Gilson expects Retrophin to post earnings per share (EPS) of -$0.58 for the fourth quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Retrophin, with an average price target of $29.5.
The analysts price targets range from a high of $38 to a low of $21.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $48.43 million and a net profit of -$23.11 million. The company's market cap is $1.09 billion.
According to TipRanks.com, Canaccord Genuity analyst Michelle Gilson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 33.3% and a 58.43% success rate.
Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.